Harmony Biosciences Holdings, Inc.
Harmony Biosciences is a neuroscience company focused on treatments for neurological diseases, including sleep and wake disorders, rare epilepsy and neurobehavioral conditions. Its commercial product is WAKIX (pitolisant), an oral treatment for excessive daytime sleepiness and cataplexy in adults and children six years and older with narcolepsy. Harmony sells WAKIX to specialty distributors, which distribute it to patients, and licenses pitolisant from Bioprojet. Its development portfolio includes next-generation pitolisant formulations, an orexin 2 receptor agonist for narcolepsy, and epilepsy candidates EPX-100 and EPX-200. Harmony also collaborates on discovery-stage cell replacement therapy candidates for treatment-resistant narcolepsy and refractory epilepsy. Its operations are conducted through wholly owned subsidiaries, and it contracts with third parties for manufacturing, storage, distribution and testing. Harmony Biosciences is headquartered in Plymouth Meeting, Pennsylvania.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $HRMY in the last 30 days.
See all $HRMY insider activity →Harmony Biosciences (HRMY) reported Q3 EPS of $0.81, missing estimates by $0.30, and revenue of $268.91M, below expectations. The company forecasts FY 2026 revenue of $1.00B-$1.04B, slightly below consensus. HRMY stock is down 3.62% over 3 months but up 18.09% year-over-year, with a Financial Health score rated 'excellent'.
Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile WAKIX ® Net Revenue in Q3 of $2
Harmony Biosciences (HRMY) reported Q3 revenue of $269M, up 12% YoY, and reaffirmed full-year guidance of $1.0B-$1.04B. Net income was $48.2M, down from $50.9M YoY. The company announced leadership changes and positive early data for BP-205. Cash reserves were $1.05B as of Q3 2026.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning HRMY (Harmony Biosciences Holdings, Inc.). Coverage has skewed bearish: 0 bullish, 3 neutral, and 3 bearish.
Recent HRMY coverage spans earnings, financial news and market movers.
Earnings miss and weaker guidance likely drive the stock lower.
Earnings release with solid revenue and unchanged guidance.
Earnings beat on revenue growth and stable guidance support modest upside; early‑stage trial data adds long‑term upside potential.
Analyst reaffirmation may cushion the recent 6% drop but does not constitute a fresh catalyst.
The patent hearing introduces legal risk, likely pressuring the stock lower.
AlphAI scores every news story that mentions HRMY with an AI model for sentiment and relevance, and aggregates insider trades from Harmony Biosciences Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Harmony Biosciences (HRMY) reported Q3 EPS of $0.81, missing estimates by $0.30, and revenue of $268.91M, below expectations. The company forecasts FY 2026 revenue of $1.00B-$1.04B, slightly below consensus. HRMY stock is down 3.62% over 3 months but up 18.09% year-over-year, with a Financial Health score rated 'excellent'.
2 min readHarmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile WAKIX ® Net Revenue in Q3 of $2
2 min readHarmony Biosciences (HRMY) reported Q3 revenue of $269M, up 12% YoY, and reaffirmed full-year guidance of $1.0B-$1.04B. Net income was $48.2M, down from $50.9M YoY. The company announced leadership changes and positive early data for BP-205. Cash reserves were $1.05B as of Q3 2026.
2 min readMizuho reiterated an Outperform rating and $51 price target for Harmony Biosciences (HRMY) after patent litigation arguments. The stock fell 6% post-arguments, but Mizuho sees no clear negative outcome. HRMY reported strong Q2 2026 earnings, with $1.28 adjusted profit per share and $261.3M revenue, beating estimates. The company maintained full-year revenue guidance of $1B-$1.04B. Other analysts also reiterated positive ratings but adjusted targets.
2 min readHarmony Biosciences (HRMY) shares dropped 7% during a court hearing on a patent for its Wakix drug. The hearing involves ANDA patent litigation between Harmony and AET Pharma in Wilmington, Delaware.
1 min readHarmony Biosciences (HRMY) will report Q3 2026 earnings on Nov. 4 before market open and host a call at 8:30 a.m. ET. The company focuses on rare neurological disease treatments. Details and webcast available on their investor relations page.
1 min readNeedham reaffirmed a Buy rating and $50 price target for Harmony Biosciences, suggesting a 31.8% upside from its Oct 16 close. Analysts expect WAKIX sales to grow from $160M in 2020 to over $700M by 2024, citing safety and convenience. The company's pipeline, including pitolisant for sleep disorders, is seen as a future growth driver.
1 min readHarmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the
4 min readHC Wainwright & Co. reiterated a Buy rating on Harmony Biosciences Hldgs with a $55 price target, suggesting a 43.9% upside from the Oct 12 close of $38.23. The firm cited the CEO's biopharmaceutical experience and the company's focus on clinical execution and product pipeline expansion.
1 min readTruist Securities previewed Q3 2026 earnings for eight biotech companies, highlighting Insmed (INSM), BridgeBio (BBIO), and Neurocrine (NBIX) for potential volatility. Insmed's Brinsupri forecast was reduced due to lower prescription trends. BridgeBio's revenue surged 202% to $713M with 94% gross margins. The FDA accepted BridgeBio's NDA for infigratinib, with analysts maintaining Buy ratings and price targets.
7 min read
